Healio13d
FDA clears investigational new drug application for Zabalafin Hydrogel
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...
Morningstar15d
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare Delivery Technology ...
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO ...
Yahoo Finance16d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
February 18, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions fo ...
Nasdaq11d
IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference
The poster details the potential of IO170 ... explore its clinical applications while we prepare for an Investigational New Drug Application (IND) submission to FDA for IO170.” ...
PharmiWeb15d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA ... the development and regulatory ...